12/3
08:00 am
anvs
Annovis To Present at the 2025 Annual Meeting of the Parkinson Study Group
Medium
Report
Annovis To Present at the 2025 Annual Meeting of the Parkinson Study Group
11/24
08:00 am
anvs
Annovis Announces Two Presentations at the CTAD 2025 Conference
High
Report
Annovis Announces Two Presentations at the CTAD 2025 Conference
11/18
08:00 am
anvs
Annovis Announces FDA Meeting to Discuss Parkinson's Disease Dementia Program; Reaffirms FDA Alignment on Pivotal Phase 3 Alzheimer's Disease Study
High
Report
Annovis Announces FDA Meeting to Discuss Parkinson's Disease Dementia Program; Reaffirms FDA Alignment on Pivotal Phase 3 Alzheimer's Disease Study
11/17
08:00 am
anvs
Annovis Reports New Biomarker Data Linking Amyloid Co-Pathology to Accelerated Cognitive Decline in Parkinson's Patients
High
Report
Annovis Reports New Biomarker Data Linking Amyloid Co-Pathology to Accelerated Cognitive Decline in Parkinson's Patients
11/12
08:00 am
anvs
Annovis Provides Corporate Updates and Reports Third Quarter 2025 Financial Results
High
Report
Annovis Provides Corporate Updates and Reports Third Quarter 2025 Financial Results
11/6
08:00 am
anvs
Annovis Achieves Significant Milestones and Sustains Strong Progress in Phase 3 Alzheimer’s Program
Medium
Report
Annovis Achieves Significant Milestones and Sustains Strong Progress in Phase 3 Alzheimer’s Program
10/27
08:00 am
anvs
Annovis Announces $3.4 Million Registered Direct Offering of Common Stock Priced At-the-Market under the NYSE Rules
High
Report
Annovis Announces $3.4 Million Registered Direct Offering of Common Stock Priced At-the-Market under the NYSE Rules
10/15
05:15 pm
anvs
Annovis Announces Closing of $6 Million Registered Direct Offering of Common Stock
High
Report
Annovis Announces Closing of $6 Million Registered Direct Offering of Common Stock
10/10
08:59 am
anvs
Annovis launches $6 million registered direct offering [Seeking Alpha]
Low
Report
Annovis launches $6 million registered direct offering [Seeking Alpha]
10/10
08:31 am
anvs
Annovis Announces $6 Million Registered Direct Offering of Common Stock
Medium
Report
Annovis Announces $6 Million Registered Direct Offering of Common Stock
10/9
08:01 am
anvs
Annovis Announces Novel Biomarker Data in Alzheimer's Patients Supporting Buntanetap's Potential as a Disease-Modifying Treatment [Yahoo! Finance]
Low
Report
Annovis Announces Novel Biomarker Data in Alzheimer's Patients Supporting Buntanetap's Potential as a Disease-Modifying Treatment [Yahoo! Finance]
10/9
07:30 am
anvs
Annovis Announces Novel Biomarker Data in Alzheimer’s Patients Supporting Buntanetap’s Potential as a Disease-Modifying Treatment
Medium
Report
Annovis Announces Novel Biomarker Data in Alzheimer’s Patients Supporting Buntanetap’s Potential as a Disease-Modifying Treatment
9/30
09:47 am
anvs
Annovis Bio (NYSE:ANVS) had its "buy" rating reaffirmed by analysts at Canaccord Genuity Group Inc.. They now have a $17.00 price target on the stock.
Low
Report
Annovis Bio (NYSE:ANVS) had its "buy" rating reaffirmed by analysts at Canaccord Genuity Group Inc.. They now have a $17.00 price target on the stock.
9/25
07:30 am
anvs
Annovis Appoints Mark Guerin as Chief Financial Officer
Low
Report
Annovis Appoints Mark Guerin as Chief Financial Officer
9/16
07:30 am
anvs
Annovis Reports Peer-Reviewed Publication Highlighting Pharmacokinetics of Novel Crystal Buntanetap
Medium
Report
Annovis Reports Peer-Reviewed Publication Highlighting Pharmacokinetics of Novel Crystal Buntanetap